comprehensive -WSS

comprehensive

author：explore 2025-09-29 23:04:11 - browse：362

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： An innovative path out of biotech’s “valley of death”

Wikipedia

WSS

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

The pink breast cancer awareness ribbon needs a redesign

FDA has safety concerns on CRISPR

Kim Kardashian sparks debate on benefits of full

Maker of FluMist seeks to allow at

Genentech weighs delaying cancer therapy after drug pricing law

focus

comprehensive

explore

Moonlake's readout produced a cash windfall. Risks remain

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Bright Health sells Medicare Advantage business to Molina

Cassava reveals details — and problems — with Alzheimer's study

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: XBI biotech index, Akero Therapeutics

Apple is now the first public company to be valued at $3 trillion

Some of the ways extreme heat will change life as we know it

Heart attack and stroke risk calculators need revising

After John Oliver segment, STAT readers share their opioid

explore

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Faced with fears of OxyContin misuse, sales reps touted its safety

TB outbreak tied to bone grafts underscores testing shortcomings

Wikipedia

entertainment

Wikipedia

focus